Welcome to our dedicated page for Psyence Biomedical Ltd. SEC filings (Ticker: PBM), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Parsing Psyence Biomedical’s SEC disclosures isn’t easy—clinical-trial protocols, Schedule I psilocybin controls, and detailed R&D burn tables fill hundreds of pages. If you need a clear view of how much runway remains before Phase 2 data or want to monitor directors� stock sales, navigating the raw documents can feel overwhelming.
Stock Titan turns that tangle into insight. Our AI-powered summaries translate each Psyence Biomedical annual report 10-K into plain English, flagging key risk factors and psilocybin manufacturing milestones. Get real-time alerts the moment a Psyence Biomedical 8-K material events filing drops, or track Psyence Biomedical insider trading Form 4 transactions without refreshing EDGAR. Looking for quarter-over-quarter cash flow? The Psyence Biomedical quarterly earnings report 10-Q filing is paired with concise revenue, R&D expense, and clinical-trial pipeline tables—ideal for comparing progress across periods.
Whether you’re checking Psyence Biomedical executive stock transactions Form 4, studying the proxy statement executive compensation details, or simply understanding Psyence Biomedical SEC documents with AI, every filing type is covered and cross-linked. Investors use these insights to spot insider sentiment before pivotal readouts, gauge dilution risk from shelf registrations, and follow licensing revenue reported in 8-Ks. Stop wading through PDFs—our AI explains Psyence Biomedical SEC filings simply while preserving every number you need.
Psyence Biomedical Ltd. (PBM) filed Form 20-F/A (Amendment No. 1) for FY ended 31 Mar 2025. The sole purpose is to add the management report on internal control over financial reporting (ICFR) that was inadvertently omitted from the original 25 Jun 2025 filing. No other sections of the annual report have been revised.
Key points:
- Management, including the CEO and CFO, evaluated ICFR and concluded controls were effective as of 31 Mar 2025.
- No material changes in ICFR occurred during the fiscal year.
- The company is a non-accelerated filer & emerging growth company; therefore, an external auditor attestation of ICFR is not required.
- Outstanding common shares at 31 Mar 2025: 568,021.
- Exhibits 12.1 and 12.2 contain re-executed Sarbanes-Oxley §302 certifications; various Inline XBRL files are also included.
The amendment does not affect previously reported financial statements or operational results and should be read in conjunction with the original Form 20-F.
Psyence Biomedical Ltd. (PBM) filed a Form S-8 to register an additional 70,174 common shares for issuance under its 2023 Equity Incentive Plan.
The new registration supplements the 3,360 shares filed on July 31, 2024, bringing the total shares registered under the plan to 73,534. The filing contains no operating results or guidance; it simply updates the share pool available for future option, RSU and other equity awards to employees, directors and consultants.
- Filer classification: non-accelerated filer, smaller reporting company, emerging growth company.
- Key exhibits include counsel’s opinion (5.1), auditor consent (23.1) and the amended equity plan (99.1).
- Incorporates by reference PBM’s Form 20-F (FY ended 3/31/25) and recent Form 6-K reports.
The S-8 is routine, involves no immediate cash proceeds and poses only minor dilution given the limited share count.
Psyence Biomedical (Nasdaq: PBM) filed its FY-2025 Form 20-F covering the year ended March 31 2025.
Key disclosures include:
- 568,021 common shares outstanding at year-end
- Securities trade as PBM (shares) and PBMWW (warrants) on Nasdaq
- Reports under IFRS; classified as a non-accelerated filer and emerging growth company
- Not a well-known seasoned issuer; no SOX 404(b) auditor attestation
- Company has no products yet approved for commercial sale and depends on successful clinical trials and regulatory clearance
- Forward-looking statements flag risks around Nasdaq listing stability, share price volatility, talent retention, supply chain, IP licensing and macro conditions
The filing provides full audited financials, risk factors and corporate-governance disclosures but does not announce new financings, M&A or product approvals.
FAQ
What is the current stock price of Psyence Biomedical Ltd. (PBM)?
What is the market cap of Psyence Biomedical Ltd. (PBM)?
What is the core business of Psyence Biomedical Ltd.?
How does Psyence Biomedical produce its psilocybin-based products?
What clinical trials is the company currently conducting?
What role do partnerships play in the company’s strategy?
How does the company ensure safety and efficacy in its products?
How does Psyence Biomedical differentiate itself within the biotech sector?
What market segments does the company target?
How does the company’s vertical integration benefit its operations?
